Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Incyte Corporation
National Cancer Institute (NCI)
Children's Oncology Group
Pfizer
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Regeneron Pharmaceuticals